Adimab

Adimab

Biotechnology, 7 Lucent Dr, Lebanon, New Hampshire, 03766, United States, 51-200 Employees

adimab.com

  • facebook
  • LinkedIn

phone no Phone Number: 60********

Who is ADIMAB

Adimab is the most successful antibody discovery company in the industry, with 450+ discovery campaigns and 55+ clinical programs created with more than 100 partners. Our unique, yeast-ba...

Read More

map

industries-icon Industry: Biotechnology

SIC SIC Code: 8731 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from ADIMAB

Adimab Org Chart and Mapping

Philip Chase

Chief Executive Officer

VP-Level

Max Vasquez

VP Computational Biology

Employees

Similar Companies to Adimab

Avitide, LLC, a Repligen Company

  • 11-50 11-50
  • 10 Million to 25 Million $ 10 Million to 25 Million

Beam Therapeutics

  • 501-1000 501-1000
  • 50 Million to 100 Million $ 50 Million to 100 Million

Bio X Cell

  • 11-50 11-50
  • 5 Million to 10 Million $ 5 Million to 10 Million
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Adimab

Answer: Adimab's headquarters are located at 7 Lucent Dr, Lebanon, New Hampshire, 03766, United States

Answer: Adimab's phone number is 60********

Answer: Adimab's official website is https://adimab.com

Answer: Adimab's revenue is $10 Million to $25 Million

Answer: Adimab's SIC: 8731

Answer: Adimab's NAICS: 541714

Answer: Adimab has 51-200 employees

Answer: Adimab is in Biotechnology

Answer: Adimab top competitors include: Avitide, LLC, a Repligen Company , Beam Therapeutics , Bio X Cell

Answer: Adimab contact info: Phone number: 60******** Website: https://adimab.com

Answer: Adimab is the most successful antibody discovery company in the industry, with 450+ discovery campaigns and 55+ clinical programs created with more than 100 partners. Our unique, yeast-based platform is a comprehensive and effective tool for the discovery and optimization of fully human monoclonal and bispecific antibodies. Our partners range from some of the biggest pharma to biotech companies at all stages to leading academic institutions. We're committed to staying at the cutting edge of protein-based therapeutic discovery to enable the highest quality IgGs, multispecifics, CARs and other modalities to allow our partners to have the most successful therapeutic programs possible.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access